{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:30:33Z","timestamp":1790901033624,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,12,2]],"date-time":"2008-12-02T00:00:00Z","timestamp":1228176000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s11095-008-9795-9","type":"journal-article","created":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T22:15:03Z","timestamp":1228169703000},"page":"926-935","source":"Crossref","is-referenced-by-count":33,"title":["A Novel Camptothecin Derivative Incorporated in Nano-Carrier Induced Distinguished Improvement in Solubility, Stability and Anti-tumor Activity Both In Vitro and In Vivo"],"prefix":"10.1007","volume":"26","author":[{"given":"Min","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Xia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Li","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yuan","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao-Jun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Zhou","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Quan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Qing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,12,2]]},"reference":[{"key":"9795_CR1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0167-4781(98)00130-4","volume":"1400","author":"C. H. Takimoto","year":"1998","unstructured":"C. H. Takimoto, J. Wright, and S. G. Arbuck. Clinical applications of the camptothecins. Biochim. Biophys. Acta. 1400:107\u2013119 (1998).","journal-title":"Biochim. Biophys. Acta"},{"key":"9795_CR2","first-page":"51","volume":"12","author":"O. Lavergne","year":"1998","unstructured":"O. Lavergne, and D. C. Bigg. The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan. Bull. Cancer. 12:51\u201358 (1998).","journal-title":"Bull. Cancer"},{"key":"9795_CR3","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1200\/JCO.2001.19.5.1501","volume":"19","author":"U. Vanhoefer","year":"2001","unstructured":"U. Vanhoefer, W. Achterrath, S. Cao, S. Seeber, and Y. M. Rustum. Irinotecan in the treatment of colorectal cancer: clinical overview. J. Clin. Oncol. 19:1501\u20131518 (2001).","journal-title":"J. Clin. Oncol."},{"key":"9795_CR4","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1055\/s-1998-2207","volume":"12","author":"Z. S. Cao","year":"1998","unstructured":"Z. S. Cao, K. Armstrong, M. Shaw, E. Petry, and N. Harris. Nitration of camptothecin with various inorganic nitrate salts in concentrated sulfuric acid: a new preparation of anticancer drug 9-nitrocamptothecin. Synthesis. 12:1724\u20131730 (1998). doi: 10.1055\/s-1998-2207 .","journal-title":"Synthesis"},{"key":"9795_CR5","first-page":"2858","volume":"29","author":"M. C. Wani","year":"1986","unstructured":"M. C. Wani, A. W. Nicholas, and M. E. Wall. Plant antitumor agents .23. Synthesis and antileukemic activity of camptothecin analogues. J. Med. Chem. 29:2858\u20132863 (1986). doi: 10.1021\/jm00161a035 .","journal-title":"J. Med. Chem."},{"key":"9795_CR6","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1016\/j.bmcl.2005.05.108","volume":"15","author":"M. Gao","year":"2005","unstructured":"M. Gao, K. D. Miller, G. W. Sledgeb, and Q. H. Zheng. Radiosynthesis of carbon-11-labeled camptothecin derivatives as potential positron emission tomography tracers for imaging of topoisomerase I in cancers. Bioorg. Med. Chem. Lett. 15:3865\u20133869 (2005). doi: 10.1016\/j.bmcl.2005.05.108 .","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"9795_CR7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.phrs.2006.06.001","volume":"54","author":"X. C. Yang","year":"2006","unstructured":"X. C. Yang, P. H. Luo, B. Yang, and Q. J. He. Antiangiogenesis response of endothelial cells to the antitumour drug 10-methoxy-9-nitrocamptothecin. Pharmacol. Res. 54:334\u2013340 (2006). doi: 10.1016\/j.phrs.2006.06.001 .","journal-title":"Pharmacol. Res."},{"key":"9795_CR8","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1158\/1535-7163.MCT-05-0385","volume":"54","author":"P. H. Luo","year":"2006","unstructured":"P. H. Luo, Q. J. He, X. G. He, Y. Z. Hu, W. Lu, Y. Y. Cheng, and B. Yang. Potent antitumor activity of 10-methoxy-9-nitrocamptothecin. Mol. Cancer. Ther. 54:962\u2013968 (2006). doi: 10.1158\/1535-7163.MCT-05-0385 .","journal-title":"Mol. Cancer. Ther."},{"key":"9795_CR9","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.bmc.2003.11.036","volume":"12","author":"C. J. Thomas","year":"2004","unstructured":"C. J. Thomas, N. J. Rahier, and S. M. Hecht. Camptothecin: current perspectives. Bioorg. Med. Chem. 12:1585\u20131604 (2004). doi: 10.1016\/j.bmc.2003.11.036 .","journal-title":"Bioorg. Med. Chem."},{"key":"9795_CR10","first-page":"827","volume":"22","author":"J. J. Zhou","year":"2001","unstructured":"J. J. Zhou, J. Liu, and B. Xu. Relationship between lactone ring forms of HCPT and their antitumor activities. Acta. Pharmacol. Sin. 22:827\u2013830 (2001).","journal-title":"Acta. Pharmacol. Sin."},{"key":"9795_CR11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1021\/jm00123a038","volume":"32","author":"R. P. Hertzberg","year":"1989","unstructured":"R. P. Hertzberg, M. J. Caranfa, K. G. Holden, D. R. Jakas, G. Gallagher, M. R. Mattern, S. M. Mong, J. O. Bartus, R. K. Johnson, and W. D. Kingsbury. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. 32:715\u2013720 (1989). doi: 10.1021\/jm00123a038 .","journal-title":"J. Med. Chem."},{"key":"9795_CR12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0169-409X(00)00102-2","volume":"45","author":"S. Kawakami","year":"2000","unstructured":"S. Kawakami, F. Yamashita, and M. Hasida. Disposition characteristics of emulsions and incorporated drugs after systemic or local injection. Adv. Drug Deliv. Rev. 45:77\u201388 (2000). doi: 10.1016\/S0169-409X(00)00102-2 .","journal-title":"Adv. Drug Deliv. Rev."},{"key":"9795_CR13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1007565230130","volume":"17","author":"P. P. Constantinides","year":"2000","unstructured":"P. P. Constantinides, K. J. Lambert, A. K. Tustian, B. Schneider, S. Lalji, W. Ma, B. Wentzel, D. Kessler, D. Worah, and S. C. Quay. Formulation development and antitumor activity of filter-sterilizable emulsion of paclitaxel. Pharm. Res. 17:175\u2013182 (2000). doi: 10.1023\/A:1007565230130 .","journal-title":"Pharm. Res."},{"key":"9795_CR14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ejpb.2007.03.016","volume":"67","author":"J. Rossi","year":"2007","unstructured":"J. Rossi, S. Giasson, M. N. Khalid, P. Delmas, C. Allen, and J. C. Leroux. Long-circulation poly (ethylene glycol)-coated emulsions to target solid tumors. Eur. J. Pharm. Biopharm. 67:329\u2013338 (2007). doi: 10.1016\/j.ejpb.2007.03.016 .","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"9795_CR15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0939-6411(98)00098-8","volume":"47","author":"K. Zurowska-Pryczkowska","year":"1999","unstructured":"K. Zurowska-Pryczkowska, M. Sznitowska, and S. Janicki. Studies on the effect of pilocarplne incorporation into a submicron emulsion on the stability of the drug and the vehicle. Eur. J. Pharm. Biopharm. 47:255\u2013260 (1999). doi: 10.1016\/S0939-6411(98)00098-8 .","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"9795_CR16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0169-409X(00)00103-4","volume":"45","author":"M. J. Lawrence","year":"2000","unstructured":"M. J. Lawrence, and G. D. Rees. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 45:89\u2013121 (2000). doi: 10.1016\/S0169-409X(00)00103-4 .","journal-title":"Adv. Drug Deliv. Rev."},{"key":"9795_CR17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cis.2003.10.026","volume":"108\u2013109","author":"O. Sonneville-Aubrun","year":"2004","unstructured":"O. Sonneville-Aubrun, J. T. Simonnet, and F. l\u2019Alloret. Nanoemulsions: a new vehicle for skincare products. Adv. Colloid Interface Sci. 108\u2013109:145\u2013149 (2004). doi: 10.1016\/j.cis.2003.10.026 .","journal-title":"Adv. Colloid Interface Sci."},{"key":"9795_CR18","doi-asserted-by":"crossref","unstructured":"L. A. Pires, R. Hegg, C. J. Valduga, S. R. Graziani, D. G. Rodrigues, and R. C. Maranhao. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemother Pharmacol., in press (2008) http:\/\/www.springerlink.com\/content\/t1452120506h7327\/ .","DOI":"10.1007\/s00280-008-0738-2"},{"key":"9795_CR19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1081\/DDC-200047802","volume":"31","author":"D. Attivi","year":"2005","unstructured":"D. Attivi. Formulation of insulin-loaded polymeric nanoparticles using response surface methodology. Drug DeV. Ind. Pharm. 31:179\u2013189 (2005). doi: 10.1081\/DDC-200047802 .","journal-title":"Drug DeV. Ind. Pharm."},{"key":"9795_CR20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.chemosphere.2007.02.066","volume":"69","author":"L. Copolovici","year":"2007","unstructured":"L. Copolovici, and U. Niinemets. Salting-in and salting-out effects of ionic and neutral osmotica on limonene and linalool Henry\u2019s law constants and octanol\/water partition coefficients. Chemosphere. 69:621\u2013629 (2007). doi: 10.1016\/j.chemosphere.2007.02.066 .","journal-title":"Chemosphere"},{"key":"9795_CR21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0378-5173(90)90381-D","volume":"66","author":"M. Y. Levy","year":"1990","unstructured":"M. Y. Levy, and S. Benita. Drug release from submicronized o\/w emulsion: new in vitro kinetic evaluation model. Int. J. Pharm. 66:29\u201337 (1990). doi: 10.1016\/0378-5173(90)90381-D .","journal-title":"Int. J. Pharm."},{"key":"9795_CR22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jcis.2004.03.015","volume":"276","author":"M. B. Moshe","year":"2004","unstructured":"M. B. Moshe, S. Magdassi, Y. Cohen, and L. Avram. Structure of microemulsions with Gemini surfactant studied by solvatochromic probe and diffusion NMR. J. Colloid Interface Sci. 276:221\u2013226 (2004). doi: 10.1016\/j.jcis.2004.03.015 .","journal-title":"J. Colloid Interface Sci."},{"key":"9795_CR23","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","volume":"82","author":"P. Skehan","year":"1990","unstructured":"P. Skehan, D. Scudiero, R. Storeng, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenney, and M. R. Boyd. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Nat. Cancer Inst. 82:1107\u20131112 (1990). doi: 10.1093\/jnci\/82.13.1107 .","journal-title":"J. Nat. Cancer Inst."},{"key":"9795_CR24","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.addr.2007.10.015","volume":"60","author":"S. S. Rane","year":"2008","unstructured":"S. S. Rane, and B. D. Anderson. What determines drug solubility in lipid vehicles: is it predictable. Adv. Drug Del. Rev. 60:638\u2013656 (2008). doi: 10.1016\/j.addr.2007.10.015 .","journal-title":"Adv. Drug Del. Rev."},{"key":"9795_CR25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1021\/js9700863","volume":"87","author":"C. Malcolmson","year":"1998","unstructured":"C. Malcolmson, C. Satra, S. Kantaria, A. Sidhu, and M. J. Lawrence. Effect of oil on the level of solubilization of testosterone propionate into nonionic oil-in-water microemulsions. J. Pharm. Sci. 87:109\u2013116 (1998). doi: 10.1021\/js9700863 .","journal-title":"J. Pharm. Sci."},{"key":"9795_CR26","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.1021\/la0001068","volume":"16","author":"H. Kunieda","year":"2000","unstructured":"H. Kunieda, N. Masuda, and K. Tsubone. Comparison between phase behavior of anionic dimeric (Gemini-Type) and monomeric surfactants in water and water-oil. Langmuir. 16:6438\u20136444 (2000). doi: 10.1021\/la0001068 .","journal-title":"Langmuir."},{"key":"9795_CR27","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1023\/A:1016274801930","volume":"12","author":"F. Liu","year":"1995","unstructured":"F. Liu, and D. Liu. Long-circulating emulsions (oil-in-water) as carriers for lipophilic drugs. Pharm. Res. 12:1060\u20131064 (1995). doi: 10.1023\/A:1016274801930 .","journal-title":"Pharm. Res."},{"key":"9795_CR28","first-page":"256","volume":"24","author":"D. F. Zhong","year":"2003","unstructured":"D. F. Zhong, K. Li, J. H. Xu, Y. Du, and Y. F. Zhang. Pharmacokinetics of 9-nitro-20(S)-camptothecin in rats. Acta Pharmacol. Sin. 24:256\u2013262 (2003).","journal-title":"Acta Pharmacol. Sin."},{"key":"9795_CR29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/156720106776359168","volume":"3","author":"P. K. Ghosh","year":"2006","unstructured":"P. K. Ghosh, and R. S. R. Murthy. Microemulsions: a potential drug delivery system. Curr. Drug Deliv. 3:167\u2013180 (2006). doi: 10.2174\/156720106776359168 .","journal-title":"Curr. Drug Deliv."},{"key":"9795_CR30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1021\/mp700091j","volume":"5","author":"J. B. Tagne","year":"2008","unstructured":"J. B. Tagne, S. Kakumanu, D. Ortiz, T. Shea, and R. J. Nicolosi. A nanoemulsion formulation of tamoxifen increases its efficacy in a breast cancer cell line. Mol. Pharm. 5:280\u2013286 (2008). doi: 10.1021\/mp700091j .","journal-title":"Mol. Pharm."},{"key":"9795_CR31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.biomaterials.2007.09.039","volume":"29","author":"T. Masuda","year":"2008","unstructured":"T. Masuda, H. Akita, T. Nishio, K. Niikura, K. Kogure, K. Ijiro, and H. Harashima. Development of lipid particles targeted via sugar-lipid conjugates as novel nuclear gene delivery system. Biomaterials. 29:709\u2013723 (2008). doi: 10.1016\/j.biomaterials.2007.09.039 .","journal-title":"Biomaterials"},{"key":"9795_CR32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0378-5173(02)00580-X","volume":"251","author":"W. Junping","year":"2003","unstructured":"W. Junping, K. Takayama, T. Nagai, and Y. Maitani. Pharmacokinetics and antitumor effects of vincristine carried by microemulsions composed of PEG-lipid, oleic acid, vitamin E and cholesterol. Int. J. Pharm. 251:13\u201321 (2003). doi: 10.1016\/S0378-5173(02)00580-X .","journal-title":"Int. J. Pharm."},{"key":"9795_CR33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1054\/drup.2000.0123","volume":"3","author":"B. A. Teicher","year":"2000","unstructured":"B. A. Teicher. Molecular targets and cancer therapeutics: discovery, development and clinical validation. Drug Resist Updat. 3:67\u201373 (2000). doi: 10.1054\/drup.2000.0123 .","journal-title":"Drug Resist Updat."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-008-9795-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-008-9795-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-008-9795-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T05:43:09Z","timestamp":1559367789000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-008-9795-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,2]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["9795"],"URL":"https:\/\/doi.org\/10.1007\/s11095-008-9795-9","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,2]]}}}